Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02042378 · ClinicalTrials.gov registry record · Phase 2
A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
A Phase 2 study, sponsored by pharmaand.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT02042378 is a Phase 2 study that has completed, run by pharmaand. The registered enrollment target is 19 participants.
The verdict
NCT02042378, a Phase 2 study, has completed, sponsored by pharmaand.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether oral rucaparib is effective in the treatment of patients with locally advanced or metastatic pancreatic cancer and a known deleterious BRCA mutation.
Interventions
- DRUG Rucaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02042378
The ClinicalTrials.gov registry entry for NCT02042378 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is pharmaand, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rucaparib is the first listed.
NCT02042378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02042378 about?
NCT02042378 is a clinical study titled "A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation". The purpose of this study is to determine whether oral rucaparib is effective in the treatment of patients with locally advanced or metastatic pancreatic cancer and a known deleterious BRCA mutation.
What is the current status of trial NCT02042378?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2014-04. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02042378?
The interventions under investigation include: Rucaparib (DRUG).
Who is sponsoring clinical trial NCT02042378?
This trial is sponsored by pharmaand, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.